Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Feb;113(2):214-218.
doi: 10.1007/s12185-020-03014-5. Epub 2020 Oct 6.

Chronic myeloid leukemia in solid organ transplant patients: a case series

Irina Amitai  1   2 , Adi Shacham Abulafia  3   4 , Pia Raanani  3   4 , Jeffrey H Lipton  5
Affiliations
Case Reports

Chronic myeloid leukemia in solid organ transplant patients: a case series

Irina Amitai et al. Int J Hematol. 2021 Feb.

Abstract

Solid organ transplant (SOT) has transformed the survival and quality of life of patients with end-organ dysfunction. Lifelong need for immunosuppressive medications prolongs life expectancy, but results in altered immune function and is associated with a higher risk of certain malignancies, including chronic myeloid leukemia (CML). In this article, we report on six patients, aged 41-79 years, diagnosed with CML, from 3 to 132 months post-various organ transplants and treated with different tyrosine kinase inhibitors (TKI), including first generation (i.e., imatinib) and second generation (i.e., dasatinib and nilotinib). Use of second-generation TKIs has not been previously reported in this population. In these six cases, treatment with different TKIs in SOT patients was feasible, well tolerated and achieved good efficacy, which was maintained in extended follow-up, as well.

Keywords: Chronic myeloid leukemia; Dasatinib; Imatinib; Nilotinib; Solid organ transplant.

PubMed Disclaimer

References

    1. Petrara MR, Giunco S, Serraino D, Dolcetti R, De Rossi A. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment. Cancer Lett. 2015;369(1):37–44. - DOI
    1. Annual data report of the US Organ Procurement and Transplantation Network (OPTN) and the Scientific Registry of Transplant Recipients (SRTR). 2018 Annual Data Report: Preface. Am J Transplant. 2020;20 Suppl s1:1–10
    1. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67. - DOI
    1. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891–901. - DOI
    1. Piselli P, Verdirosi D, Cimaglia C, Busnach G, Fratino L, Ettorre GM, et al. Epidemiology of de novo malignancies after solid-organ transplantation: immunosuppression, infection and other risk factors. Best Pract Res Clin Obstet Gynaecol. 2014;28(8):1251–65. - DOI

Publication types

MeSH terms

LinkOut - more resources